阿法骨化醇对高血压颈动脉粥样硬化患者血尿酸、C反应蛋白和补体的影响

The Effect of Alfacalcidol on the Serum Levels of CRP,BUA and Complement in Patients with Hypertension and Carotid Artherosclerosis

目的观察阿法骨化醇对老年高血压合并颈动脉粥样硬化(CAS)患者血尿酸(BUA)、补体C3和血清C-反应蛋白(CRP)水平的影响。方法随机选择122例老年高血压合并CAS患者分为两组。治疗组:65例患者口服阿法骨化醇加常规药物治疗3月。对照组:57例患者接受常规药物治疗3月。比较治疗前后患者的血压、血糖、血脂、肾功能、CRP、C3和BUA水平的变化。结果阿法骨化醇治疗组患者治疗后CRP、C3和BUA水平明显低于治疗前(P<0.05);对照组患者治疗前后CRP、C3和BUA的水平差异无统计学意义(P>0.05)。结论阿法骨化醇能够降低老年高血压病合并CAS患者的CRP、C3和BUA水平,可能对防治动脉粥样硬化有着积极的作用。

Objective To observe the effect of Alfacalcidol on the level of C - reactive protein （CRP）. C3 and blood uric acid （BUA） in serum of elderly patients with hypertension and carotid artherosclerosis. Methods There were 122 elderly patients with hypertension and carotid artheroselerosis divided into two groups. In treatment group, there were 65 elderly patients who were treated with Alfaealcidol and routine drugs, In control group, there were 57 elderly patients who were treated with routine drugs. The levels of blood calcium, blood phosphonium, CRP, C3 and BUA, renal function pre -and posttreatment were detected. The levels were compared between pre - and posttreatment. Results In treatment group, the levels of CRP, C3 and BUA after treatment were lower than those of before treatment. The difference was significant （ P 〈 0. 05 ）. There was no signifi- cant difference in control group. Conclusion Alfacalcidol can decrease the levels of CRP, C3 and BUA in elderly patients with hypertension and carotid artherosclerosis and has positive effect on early prevention and therapy of artheroselerosis.